SAB Total Other Income Expense Net from 2010 to 2024
| SABSW Stock | USD 0.07 0 5.75% |
Total Other Income Expense Net | First Reported 2010-12-31 | Previous Quarter -4.1 M | Current Value -3.9 M | Quarterly Volatility 3.3 M |
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 3.9 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
SAB | Total Other Income Expense Net |
Latest SAB Biotherapeutics' Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of SAB Biotherapeutics over the last few years. It is SAB Biotherapeutics' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
SAB Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | (343,094) | |
| Geometric Mean | 669,322 | |
| Coefficient Of Variation | (953.53) | |
| Mean Deviation | 1,446,531 | |
| Median | (312,749) | |
| Standard Deviation | 3,271,492 | |
| Sample Variance | 10.7T | |
| Range | 14.3M | |
| R-Value | (0.05) | |
| Mean Square Error | 11.5T | |
| R-Squared | 0 | |
| Significance | 0.87 | |
| Slope | (34,250) | |
| Total Sum of Squares | 149.8T |
SAB Total Other Income Expense Net History
About SAB Biotherapeutics Financial Statements
SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Other Income Expense Net | -4.1 M | -3.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.